Overview

Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients with Bietti Crystalline Dystrophy

Status:
NOT_YET_RECRUITING
Trial end date:
2027-06-30
Target enrollment:
Participant gender:
Summary
This is a phase 3 study to evaluate the efficacy and safety of VGR-R01 in subjects with Bietti Crystalline Dystrophy. This is a multicenter, randomized controlled study which will enroll 45 subjects.
Phase:
PHASE3
Details
Lead Sponsor:
Shanghai Vitalgen BioPharma Co., Ltd.